查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2010979

脑生物标记市场：按生物标记类型、疾病、检体类型、技术和最终用户划分－2026年至2032年全球市场预测

Brain Biomarkers Market by Biomarker Type, Disease Indication, Sample Type, Technology, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，脑生物标记市场价值将达到 125 亿美元，到 2026 年将成长至 146.4 亿美元，到 2032 年将达到 407.4 亿美元，年复合成长率为 18.37%。

主要市场统计数据
基准年 2025 125亿美元
预计年份：2026年 146.4亿美元
预测年份 2032 407.4亿美元
复合年增长率 (%) 18.37%

综合介绍塑造脑生物标记开发和传播未来的科学、临床、监管和商业性基础。

随着分子生物学、成像技术和计算分析的融合，脑生物标记的探索和商业化正在迅速推进，从而催生出更精准的诊断和预后工具。近期科学突破提高了神经退化性疾病疾病和急性神经系统疾病候选生物标记的敏感性和特异性，同时，检体处理、数位诊断和法规结构的同步发展也使得临床检验流程更加高效。本文概述了关键驱动因素、相关人员的需求以及核心科学范式，旨在为研究人员、临床医生、投资者和产业领导者提供策略决策支援。

对加速多模态脑生物标记检验和临床应用的技术、监管和合作变革的融合进行了详细分析。

在脑生物标记领域，正在发生多项变革性变化，这些变化正在重新定义研究重点和商业化路径。首先，精准医疗的需求正推动该领域从基于单一分析物的测量转向结合遗传资讯、蛋白质体学、代谢物和影像学资讯的多模态态特征。分析灵敏度的提高和更丰富的纵向资料集为这一整合趋势提供了支持，这些因素共同增强了生物标记组合和演算法决策支援工具的临床意义。

2025 年美国关税调整对脑生物标记倡议的采购、供应链韧性和商业化计画的营运和策略影响。

政策环境正在影响供应链、试剂成本、仪器采购和跨境合作，而美国近期针对2025年实施的关税调整，也为价值链上的相关人员带来了新的营运考量。关税调整影响了进口仪器组件、特殊试剂和实验室耗材，迫使采购团队重新评估其筹资策略和成本结构。为此，许多机构加强了供应商多元化，透过谈判签订长期合约来降低价格波动风险，并加快了供应商选择流程，以确保关键检测的连续性。

整合全面的细分，以识别生物标记类型、适应症、检体基质、技术和最终用户的交集，并确定开发和部署的优先事项。

一套精细的细分框架清晰地展现了科学机会与商业性需求之间的交集。就生物标记的类型而言，遗传标记包括基因表现标记、 微型RNA标记和单核苷酸多态性（SNP）标誌物，每种标记物在阐明疾病机制和预测分析方面都具有独特的优势。诸如电脑断层扫描（CT）、磁振造影（MRI）和正子断层扫描（PET）等影像技术能够提供高空间解析度的解剖和功能数据，是对分子层级测量的补充。代谢物检测涵盖脂质代谢物和小分子代谢物，可以反映动态的生化状态和代谢异常。同时，在脑脊髓液、血浆和唾​​液中检测的蛋白质生物标记具有不同的灵敏度和可及性，适用于临床应用。

影响美洲、欧洲、中东、非洲和亚太地区临床检验、监管流程和商业化策略的区域趋势。

区域趋势对美洲、欧洲、中东和非洲以及亚太地区的科学研究合作、监管预期、报销环境和基础设施投资都产生了重大影响。在美洲，健全的临床研究网络和完善的支付体系为后期检验和支付方合作提供了有利环境，而大量的私人和公共资金支持着转化研究和技术商业化。该地区也聚集了许多先进的诊断实验室和大学附属医院，能够进行复杂的多中心研究并产生真实世界数据（REW）。

策略竞争分析表明，平台整合、伙伴关係和严格的临床检验是脑生物标记生态系统中主要参与者的关键差异化因素。

在脑生物标记生态系统中，主要企业正透过整合平台策略、策略伙伴关係以及对临床检验的投资来展现其真实世界价值，从而实现差异化竞争。成功的企业将深厚的检测开发专业知识与可扩展的生产流程和监管经验相结合，以应对复杂的核准和报销环境。诊断公司、设备製造商、製药公司和学术机构之间的合作关係能够加速获取临床检体，扩大检验队列，并为与治疗项目相关的伴随诊断的共同开发铺平道路。

为领导者提供实用建议，以协调证据产生、供应链韧性和个人化商业化策略，从而加速临床部署。

产业领导者应优先产生与临床决策要点和支付方价值框架相符的证据，以加速生物标记的应用和报销。透过设计前瞻性效用研究，展示基于生物标记的决策如何改善患者预后或优化资源利用，可以强化价值主张并降低提案障碍。同时，各机构应投资于结合基因、蛋白质、代谢物和影像数据的多模态检验策略，以提高诊断准确性，并为治疗决策提供更丰富的背景资讯。

高度透明的调查方法，结合一手访谈、二手文献回顾和严谨的分析框架，确保了可重复性和可操作性的见解。

本报告整合了第一手和第二手研究、专家访谈以及严谨的方法论框架，以确保提供可靠且透明的洞见。第一手研究包括对临床研究人员、检查室管理人员、行业高管和保险公司进行的结构化访谈，从而提供关于营运挑战、检验重点和应用驱动因素的实证见解。第二手研究则利用同侪审查文献、监管指导文件和技术白皮书，全面检验诊断技术应用的技术性能特征和历史案例研究。

结论整合强调了实现生物标誌物影响所必需的综合证据策略、营运灵活性和跨部门合作。

总之，脑生物标记领域正处于一个转折点，科学进步、技术成熟和政策环境的变化共同为改善多种神经系统疾病的诊断、监测和治疗方法研发创造了实际机会。要充分发挥这一潜力，需要精心整合多模态数据，设计能够证明临床效用的可操作检验方案，并建立一个能够适应供应链和政策波动的稳健运作框架。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：脑生物标记市场－依生物标记类型划分

  • 基因
    • 基因表现标记
    • miRNA标记物
    • SNP标记
  • 诊断影像
    • CT
    • MRI
    • PET
  • 代谢物
    • 脂质代谢物
    • 小分子代谢物
  • 蛋白质
    • 脑脊髓液（CSF）蛋白
    • 电浆番茄
    • 唾液蛋白

第九章：脑生物标记市场：依疾病指征划分

  • 阿兹海默症
  • 癫痫
  • 多发性硬化症
  • 帕金森氏症
  • 中风

第十章：依检体类型分類的脑生物标记市场

  • 血
    • 电浆
    • 血清
  • 脑脊髓液
  • 唾液
  • 尿

第十一章 脑生物标记市场：依技术划分

  • 层析法
  • 免疫检测
  • 质谱分析
  • 次世代定序
  • PCR

第十二章 脑生物标记市场：依最终用户划分

  • 合约研究机构
  • 诊断检测实验室
  • 医院
  • 製药公司
  • 研究机构

第十三章 脑生物标记市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 脑生物标记市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 脑生物标记市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国脑生物标记市场

第十七章：中国脑生物标记市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • ADx NeuroSciences NV
  • Amprion, Inc.
  • Banyan Biomarkers, Inc.
  • Biogen Inc.
  • C2N Diagnostics, LLC
  • DiaSorin SpA
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Fujirebio Diagnostics, Inc.
  • Janssen Pharmaceuticals, Inc.
  • Merck KGaA
  • Mesoscale Discovery, LLC
  • Novartis AG
  • Quanterix Corporation
  • Quretec Ltd.
  • Roche Holding AG
  • Siemens Healthineers AG
Product Code: MRR-43150DF82D01

The Brain Biomarkers Market was valued at USD 12.50 billion in 2025 and is projected to grow to USD 14.64 billion in 2026, with a CAGR of 18.37%, reaching USD 40.74 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 12.50 billion
Estimated Year [2026] USD 14.64 billion
Forecast Year [2032] USD 40.74 billion
CAGR (%) 18.37%

An integrated introduction outlining the scientific, clinical, regulatory, and commercial foundations shaping the future of brain biomarker development and adoption

The landscape of brain biomarker research and commercialization is rapidly advancing as molecular biology, imaging modalities, and computational analytics converge to create more precise diagnostic and prognostic tools. Recent scientific breakthroughs have improved the sensitivity and specificity of candidate biomarkers across neurodegenerative and acute neurological conditions, while parallel progress in sample processing, digital diagnostics, and regulatory frameworks is enabling more streamlined clinical validation pathways. This introduction frames the key drivers, stakeholder needs, and core scientific paradigms that inform strategic decisions for researchers, clinicians, investors, and industry leaders.

Understanding this field requires an integrated perspective that connects technology platforms with clinical endpoints and end-user adoption dynamics. Advances in genetic profiling, expanded imaging capabilities, and enhanced biofluid assays are increasingly capable of delivering clinically actionable insights earlier in disease trajectories. At the same time, healthcare systems are under pressure to prioritize diagnostics that improve outcomes, reduce cost of care, and support personalized therapeutic approaches.

This section sets the stage for the executive summary by outlining how converging scientific, regulatory, and commercial forces are reshaping priorities. It highlights the importance of cross-disciplinary collaboration, robust validation standards, and strategic investments to translate promising biomarkers from discovery into routine clinical use. By establishing these foundational themes, the reader can better interpret subsequent analysis on shifts in the landscape, segmentation nuances, regional dynamics, company strategies, and actionable recommendations.

Detailed analysis of converging technological, regulatory, and collaborative shifts that are accelerating multimodal brain biomarker validation and clinical adoption

The brain biomarker landscape is experiencing several transformative shifts that are redefining research priorities and commercialization pathways. First, precision medicine imperatives are moving the field beyond single-analyte readouts toward multimodal signatures that combine genetic, proteomic, metabolite, and imaging-derived information. This integrative trend is supported by improved analytic sensitivity and richer longitudinal datasets, which together elevate the clinical relevance of biomarker panels and algorithmic decision-support tools.

Second, technology maturation is accelerating throughput and reducing assay costs, thereby enabling broader deployment in both research and clinical settings. High-resolution imaging protocols and next generation sequencing platforms have become more accessible, while mass spectrometry and advanced immunoassays are delivering higher reproducibility for biofluid-based markers. These capabilities are complemented by digital health tools that facilitate remote sample collection and real-world data capture, strengthening evidence generation across diverse patient cohorts.

Third, regulatory approaches and payer considerations are shifting to accommodate novel diagnostics that demonstrate clear clinical utility. Health systems and payers are increasingly focused on value-based evidence linking biomarker use to improved patient outcomes, pathway efficiencies, or cost offsets. Consequently, sponsors are adapting study designs to emphasize prospective clinical utility, health economics, and implementation feasibility.

Finally, collaborative models are emerging as essential to accelerate validation and adoption. Public-private partnerships, data consortia, and multi-center clinical networks are addressing reproducibility challenges and enabling larger, more diverse validation cohorts. Taken together, these shifts create a dynamic environment in which innovation, evidence rigor, and practical deployment strategies must align to realize the full potential of brain biomarkers.

Operational and strategic ramifications of recent United States tariff adjustments in 2025 shaping procurement, supply chain resilience, and commercialization planning for brain biomarker initiatives

The policy environment influences supply chains, reagent costs, instrument procurement, and cross-border collaborations, and recent tariff changes in the United States for 2025 introduced new operational considerations for stakeholders across the value chain. Tariff adjustments affected imported instrumentation components, specialized reagents, and laboratory consumables, prompting procurement teams to reassess sourcing strategies and cost structures. In response, many organizations intensified supplier diversification, negotiated long-term contracts to mitigate price volatility, and accelerated vendor qualification processes to maintain continuity of critical assays.

Supply chain recalibration extended to international partnerships, where collaborative research programs reassessed timelines and logistical workflows to account for potential customs delays and higher landed costs. These operational adjustments had a downstream effect on research throughput and pilot study timelines, particularly for programs reliant on imported imaging hardware, sequencing reagents, and high-sensitivity assay kits. Consequently, study planners prioritized critical-path items and adopted phased validation approaches to preserve momentum while containing near-term cost pressures.

Tariff-induced shifts also highlighted the strategic value of domestic manufacturing and local partnerships. Stakeholders exploring co-development and contract manufacturing agreements sought to build redundancy and reduce exposure to trade policy fluctuations. Where local supply alternatives were limited, organizations invested in robust inventory strategies and instituted adaptive budgeting to absorb episodic cost increases without compromising study integrity.

Finally, these trade policy dynamics underscored the need for flexible commercialization strategies. Companies seeking to enter or expand in the U.S. market recalibrated pricing models, refined value propositions to justify list pricing changes, and engaged payers earlier to reinforce reimbursement narratives. In sum, the 2025 tariff adjustments catalyzed pragmatic operational shifts and encouraged longer-term investments in supply chain resilience and localized capabilities.

Comprehensive segmentation synthesis revealing where biomarker type, indication, sample matrix, technology, and end user converge to prioritize development and adoption pathways

A nuanced segmentation framework brings clarity to where scientific opportunity and commercial traction intersect. Considering biomarker type, genetic markers encompass gene expression markers, microRNA markers, and single nucleotide polymorphism markers, each offering distinct advantages in terms of disease mechanism insight and potential for predictive analytics. Imaging modalities including computed tomography, magnetic resonance imaging, and positron emission tomography deliver spatially resolved anatomical and functional data that complement molecular readouts. Metabolite assays span lipid metabolites and small molecule metabolites, which can reflect dynamic biochemical states and metabolic dysregulation, while protein-based biomarkers measured in cerebrospinal fluid, plasma, and saliva offer varied sensitivity and accessibility profiles for clinical use.

When evaluating disease indications, priority areas such as Alzheimer's disease, epilepsy, multiple sclerosis, Parkinson's disease, and stroke illustrate diverse validation pathways and clinical endpoints. Each indication presents unique requirements for diagnostic accuracy, longitudinal monitoring, and therapeutic impact, shaping both technical development and clinical study design. Sample type segmentation further refines feasibility and adoption considerations: blood-based approaches, including plasma and serum, offer minimally invasive sampling suitable for broader screening and longitudinal monitoring, while cerebrospinal fluid provides proximity to central nervous system pathology and greater analytical sensitivity. Saliva and urine represent convenient matrices for decentralized collection but often require enhanced assay sensitivity to reach clinical utility.

Technology platform selection matters for analytical performance and scalability. Chromatography techniques such as HPLC and UHPLC, immunoassays including ELISA and lateral flow assays, mass spectrometry variants like GC-MS and LC-MS, next generation sequencing approaches encompassing targeted and whole genome sequencing, and PCR modalities including digital PCR and qPCR each present trade-offs in throughput, sensitivity, and regulatory maturity. End-user segmentation comprising contract research organizations, diagnostic laboratories, hospitals, pharmaceutical companies, and research institutes shapes commercialization and service delivery strategies, as adoption timelines and procurement processes differ substantially across these buyer groups. Integrating these layers of segmentation reveals prioritized development pathways where modality, indication, sample type, and technology align to achieve feasible clinical and commercial outcomes.

Regional dynamics shaping clinical validation, regulatory pathways, and commercialization strategies across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics materially influence research collaborations, regulatory expectations, reimbursement environments, and infrastructure investments across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, robust clinical research networks and established payer systems provide a conducive environment for late-stage validation and payer engagement, while significant private and public funding streams support translational initiatives and technology commercialization. This region also exhibits substantial concentration of advanced diagnostic laboratories and academic medical centers that can execute complex multi-center studies and real-world evidence generation.

Europe, the Middle East & Africa presents a heterogeneous landscape where regulatory harmonization efforts, centralized health technology assessment frameworks, and diverse healthcare delivery models shape adoption pathways. Several markets within this region prioritize early diagnostic interventions and national screening programs, creating opportunities for validated biomarkers that demonstrate population-level benefit. Meanwhile, emerging markets across the Middle East & Africa are rapidly building diagnostic infrastructure and forming strategic partnerships to access advanced technologies.

Asia-Pacific is characterized by substantial investment in biotech and diagnostic manufacturing, fast-growing clinical trial capacity, and a rapidly expanding patient population. Regulatory reforms and initiatives to strengthen local manufacturing are accelerating market entry for novel diagnostics, while digital health adoption and telemedicine expansion support decentralized testing and longitudinal patient monitoring. Cross-border collaborations between research institutes and industry partners in the region are enhancing access to diverse patient cohorts and facilitating accelerated validation of biomarkers across different genetic and environmental backgrounds.

Across all regions, stakeholders must tailor evidence generation, regulatory strategy, and commercialization plans to local payer expectations, clinical practice patterns, and infrastructure capabilities. Recognizing these distinctions enables targeted market entry approaches and more effective global coordination of multi-site clinical programs.

Strategic competitive analysis highlighting how platform integration, partnerships, and rigorous clinical validation differentiate leading players in the brain biomarker ecosystem

Key companies operating in the brain biomarker ecosystem are differentiating through integrated platform strategies, strategic partnerships, and investment in clinical validation to demonstrate real-world value. Successful organizations combine deep domain expertise in assay development with scalable manufacturing processes and regulatory know-how to navigate complex approval and reimbursement landscapes. Collaborative alliances between diagnostics firms, instrument manufacturers, pharmaceutical sponsors, and academic centers accelerate access to clinical samples, expand validation cohorts, and create co-development pathways for companion diagnostics linked to therapeutic programs.

Leadership strategies also emphasize portfolio diversification across modalities to hedge technical risk and address a broader set of disease indications. Companies that invest in modular, interoperable platforms - for example, assays that can be adapted across CSF, plasma, or saliva matrices, or analytical pipelines that harmonize imaging and molecular data - position themselves to serve multiple customers and use cases. In addition, firms that demonstrate transparent analytical validation and publish peer-reviewed performance data foster greater clinician and payer trust, smoothing adoption hurdles.

Smaller, innovation-driven companies often focus on niche assays or enabling technologies such as novel reagents, algorithms, or sample preservation solutions, creating acquisition or licensing targets for larger players. Meanwhile, established diagnostic and instrument companies leverage global distribution networks and regulatory experience to scale validated solutions rapidly. Across the competitive landscape, the balance between internal R&D, external partnerships, and strategic M&A determines speed to market and ability to achieve sustainable commercial traction.

Actionable recommendations for leaders to align evidence generation, supply chain resilience, and tailored commercialization strategies that accelerate clinical adoption

Industry leaders should prioritize evidence generation that aligns with clinical decision points and payer value frameworks to accelerate adoption and reimbursement. Designing prospective utility studies that demonstrate how biomarker-informed decisions improve patient outcomes or optimize resource use will strengthen value propositions and reduce adoption friction. Simultaneously, organizations should invest in multimodal validation strategies that combine genetic, protein, metabolite, and imaging data to enhance diagnostic precision and provide richer context for therapeutic decision-making.

Operationally, companies must build resilient supply chains and flexible manufacturing arrangements to mitigate policy and trade-related disruptions. Localized production capabilities, qualified secondary suppliers, and dynamic inventory models will minimize the impact of external shocks and preserve continuity for critical assays. In parallel, strengthening data interoperability and standardized reporting will make it easier for clinical laboratories and health systems to integrate new biomarkers into existing workflows and electronic health record systems.

Commercially, stakeholders should tailor go-to-market strategies to specific end-user needs, recognizing that hospitals, diagnostic labs, research institutes, contract research organizations, and pharmaceutical companies require different evidence packages, service models, and pricing approaches. Early engagement with payers and health technology assessment bodies can refine study endpoints and evidence generation plans to align with reimbursement criteria. Finally, leaders should pursue strategic collaborations and consortium participation to access diverse patient cohorts, share validation costs, and accelerate consensus on clinical utility standards.

Transparent research methodology combining primary interviews, secondary literature review, and rigorous analytic frameworks to ensure reproducible and actionable insights

This report synthesizes primary and secondary research, expert interviews, and rigorous methodological frameworks to ensure robust and transparent findings. Primary research included structured interviews with clinical investigators, laboratory directors, industry executives, and payers, providing grounded insights into operational challenges, validation priorities, and adoption drivers. Secondary research drew upon peer-reviewed literature, regulatory guidance documents, and technology white papers to triangulate technical performance characteristics and historical precedent for diagnostic adoption.

Analytical methods included qualitative thematic analysis of stakeholder interviews, cross-validation of technology capability claims against published analytical validation studies, and scenario-based assessment of operational impacts arising from policy changes. Special attention was paid to the reproducibility of assay performance across sample matrices and sites, and to the alignment of clinical endpoints with regulatory and payer evidence expectations. The methodology emphasized transparency: criteria for study inclusion, interview protocols, and analytic assumptions are documented in appendices to support reproducibility and allow readers to assess applicability to their own programs.

Where appropriate, sensitivity analyses explored alternative operational pathways and evidence strategies to highlight risk mitigations and strategic trade-offs. The combined approach ensures that recommendations reflect both empirical data and practical feasibility, providing stakeholders with a rigorous foundation for planning scientific programs, clinical validation, and commercialization tactics.

Concluding synthesis emphasizing the imperative for integrated evidence strategies, operational agility, and cross-sector collaboration to realize biomarker impact

In conclusion, the brain biomarker field stands at an inflection point where scientific advances, technological maturity, and evolving policy environments create tangible opportunities to improve diagnosis, monitoring, and therapeutic development across multiple neurological conditions. Realizing this potential requires deliberate integration of multimodal data, pragmatic validation designs that demonstrate clinical utility, and resilient operational frameworks that accommodate supply chain and policy variability.

Strategic alignment among developers, clinical research networks, payers, and healthcare providers will accelerate translation from promising markers to routine clinical practice. Investments in interoperable platforms, rigorous analytical validation, and early payer engagement will be essential to secure adoption and reimbursement. Additionally, regional strategies tailored to local regulatory expectations and infrastructure capacities will enhance global deployment prospects.

Ultimately, organizations that combine scientific rigor with operational foresight and collaborative partnerships will lead the next wave of innovation in brain biomarkers. The path forward is collaborative and evidence-driven, and stakeholders that prioritize value for patients and health systems will unlock the greatest clinical and commercial impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Brain Biomarkers Market, by Biomarker Type

  • 8.1. Genetic
    • 8.1.1. Gene Expression Markers
    • 8.1.2. Mirna Markers
    • 8.1.3. Snp Markers
  • 8.2. Imaging
    • 8.2.1. CT
    • 8.2.2. MRI
    • 8.2.3. PET
  • 8.3. Metabolite
    • 8.3.1. Lipid Metabolites
    • 8.3.2. Small Molecule Metabolites
  • 8.4. Protein
    • 8.4.1. CSF Proteins
    • 8.4.2. Plasma Proteins
    • 8.4.3. Saliva Proteins

9. Brain Biomarkers Market, by Disease Indication

  • 9.1. Alzheimer's Disease
  • 9.2. Epilepsy
  • 9.3. Multiple Sclerosis
  • 9.4. Parkinson's Disease
  • 9.5. Stroke

10. Brain Biomarkers Market, by Sample Type

  • 10.1. Blood
    • 10.1.1. Plasma
    • 10.1.2. Serum
  • 10.2. Cerebrospinal Fluid
  • 10.3. Saliva
  • 10.4. Urine

11. Brain Biomarkers Market, by Technology

  • 11.1. Chromatography
  • 11.2. Immunoassay
  • 11.3. Mass Spectrometry
  • 11.4. Next Generation Sequencing
  • 11.5. PCR

12. Brain Biomarkers Market, by End User

  • 12.1. Contract Research Organizations
  • 12.2. Diagnostic Laboratories
  • 12.3. Hospitals
  • 12.4. Pharmaceutical Companies
  • 12.5. Research Institutes

13. Brain Biomarkers Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Brain Biomarkers Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Brain Biomarkers Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Brain Biomarkers Market

17. China Brain Biomarkers Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. ADx NeuroSciences NV
  • 18.7. Amprion, Inc.
  • 18.8. Banyan Biomarkers, Inc.
  • 18.9. Biogen Inc.
  • 18.10. C2N Diagnostics, LLC
  • 18.11. DiaSorin S.p.A.
  • 18.12. Eli Lilly and Company
  • 18.13. F. Hoffmann-La Roche AG
  • 18.14. Fujirebio Diagnostics, Inc.
  • 18.15. Janssen Pharmaceuticals, Inc.
  • 18.16. Merck KGaA
  • 18.17. Mesoscale Discovery, LLC
  • 18.18. Novartis AG
  • 18.19. Quanterix Corporation
  • 18.20. Quretec Ltd.
  • 18.21. Roche Holding AG
  • 18.22. Siemens Healthineers AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL BRAIN BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BRAIN BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BRAIN BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BRAIN BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BRAIN BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY GENETIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY GENETIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY GENETIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY GENETIC, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY GENE EXPRESSION MARKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY GENE EXPRESSION MARKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY GENE EXPRESSION MARKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY MIRNA MARKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY MIRNA MARKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY MIRNA MARKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SNP MARKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SNP MARKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SNP MARKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY MRI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY MRI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY MRI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY METABOLITE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY METABOLITE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY METABOLITE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY METABOLITE, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY LIPID METABOLITES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY LIPID METABOLITES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY LIPID METABOLITES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SMALL MOLECULE METABOLITES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SMALL MOLECULE METABOLITES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SMALL MOLECULE METABOLITES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PROTEIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PROTEIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PROTEIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CSF PROTEINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CSF PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CSF PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PLASMA PROTEINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PLASMA PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PLASMA PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SALIVA PROTEINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SALIVA PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SALIVA PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY EPILEPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PARKINSON'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PARKINSON'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY STROKE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY STROKE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY STROKE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SERUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SERUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CEREBROSPINAL FLUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CEREBROSPINAL FLUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CEREBROSPINAL FLUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SALIVA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SALIVA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY URINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY URINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY URINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CHROMATOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CHROMATOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CHROMATOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY GENETIC, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY METABOLITE, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA BRAIN BIOMARKERS MARKET SIZE, BY GENETIC, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA BRAIN BIOMARKERS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA BRAIN BIOMARKERS MARKET SIZE, BY METABOLITE, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA BRAIN BIOMARKERS MARKET SIZE, BY PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA BRAIN BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA BRAIN BIOMARKERS MARKET SIZE, BY GENETIC, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA BRAIN BIOMARKERS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA BRAIN BIOMARKERS MARKET SIZE, BY METABOLITE, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA BRAIN BIOMARKERS MARKET SIZE, BY PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA BRAIN BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA BRAIN BIOMARKERS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA BRAIN BIOMARKERS MARKET SIZE, BY GENETIC, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA BRAIN BIOMARKERS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA BRAIN BIOMARKERS MARKET SIZE, BY METABOLITE, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA BRAIN BIOMARKERS MARKET SIZE, BY PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA BRAIN BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE BRAIN BIOMARKERS MARKET SIZE, BY GENETIC, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE BRAIN BIOMARKERS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE BRAIN BIOMARKERS MARKET SIZE, BY METABOLITE, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE BRAIN BIOMARKERS MARKET SIZE, BY PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE BRAIN BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST BRAIN BIOMARKERS MARKET SIZE, BY GENETIC, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST BRAIN BIOMARKERS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST BRAIN BIOMARKERS MARKET SIZE, BY METABOLITE, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST BRAIN BIOMARKERS MARKET SIZE, BY PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST BRAIN BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA BRAIN BIOMARKERS MARKET SIZE, BY GENETIC, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA BRAIN BIOMARKERS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA BRAIN BIOMARKERS MARKET SIZE, BY METABOLITE, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA BRAIN BIOMARKERS MARKET SIZE, BY PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA BRAIN BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY GENETIC, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY METABOLITE, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN BRAIN BIOMARKERS MARKET SIZE, BY GENETIC, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN BRAIN BIOMARKERS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN BRAIN BIOMARKERS MARKET SIZE, BY METABOLITE, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN BRAIN BIOMARKERS MARKET SIZE, BY PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN BRAIN BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. GCC BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. GCC BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. GCC BRAIN BIOMARKERS MARKET SIZE, BY GENETIC, 2018-2032 (USD MILLION)
  • TABLE 224. GCC BRAIN BIOMARKERS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 225. GCC BRAIN BIOMARKERS MARKET SIZE, BY METABOLITE, 2018-2032 (USD MILLION)
  • TABLE 226. GCC BRAIN BIOMARKERS MARKET SIZE, BY PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 227. GCC BRAIN BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 228. GCC BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. GCC BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 230. GCC BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 231. GCC BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION BRAIN BIOMARKERS MARKET SIZE, BY GENETIC, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION BRAIN BIOMARKERS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION BRAIN BIOMARKERS MARKET SIZE, BY METABOLITE, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION BRAIN BIOMARKERS MARKET SIZE, BY PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION BRAIN BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS BRAIN BIOMARKERS MARKET SIZE, BY GENETIC, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS BRAIN BIOMARKERS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS BRAIN BIOMARKERS MARKET SIZE, BY METABOLITE, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS BRAIN BIOMARKERS MARKET SIZE, BY PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS BRAIN BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. G7 BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 255. G7 BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. G7 BRAIN BIOMARKERS MARKET SIZE, BY GENETIC, 2018-2032 (USD MILLION)
  • TABLE 257. G7 BRAIN BIOMARKERS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 258. G7 BRAIN BIOMARKERS MARKET SIZE, BY METABOLITE, 2018-2032 (USD MILLION)
  • TABLE 259. G7 BRAIN BIOMARKERS MARKET SIZE, BY PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 260. G7 BRAIN BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 261. G7 BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. G7 BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 263. G7 BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 264. G7 BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 265. NATO BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 266. NATO BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. NATO BRAIN BIOMARKERS MARKET SIZE, BY GENETIC, 2018-2032 (USD MILLION)
  • TABLE 268. NATO BRAIN BIOMARKERS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 269. NATO BRAIN BIOMARKERS MARKET SIZE, BY METABOLITE, 2018-2032 (USD MILLION)
  • TABLE 270. NATO BRAIN BIOMARKERS MARKET SIZE, BY PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 271. NATO BRAIN BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 272. NATO BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. NATO BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 274. NATO BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 275. NATO BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, BY GENETIC, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, BY METABOLITE, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, BY PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA BRAIN BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. CHINA BRAIN BIOMARKERS MARKET SIZE, BY GENETIC, 2018-2032 (USD MILLION)
  • TABLE 291. CHINA BRAIN BIOMARKERS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 292. CHINA BRAIN BIOMARKERS MARKET SIZE, BY METABOLITE, 2018-2032 (USD MILLION)
  • TABLE 293. CHINA BRAIN BIOMARKERS MARKET SIZE, BY PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA BRAIN BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 295. CHINA BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. CHINA BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 297. CHINA BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 298. CHINA BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)